Singapore: Kinex Pharmaceuticals has got approval from the US FDA for its Investigational New Drug (IND) application for...
Singapore: Mr Murali Muthuswamy Panchapagesa, managing director of Evolva Holdings said that the firm is partnering with...
Singapore: Viropro has signed a biosimilars collaboration agreement with New Jersey-based Oncobiologics for the rights t...
The global bioscience industry, in 2012, reported 450 mergers and acquisitions (M&A) transactions valued at $67 bill...
Singapore: British Standards Institution (BSI), the business standards company, has been registered by the Malaysian Med...
Mr Rizatuddin Ramli, CEO, Bio-XCell, Malaysia, is on his toes to deliver the objectives of phase II of Malaysia's Nation...
Bio-XCell, a custom-built biotechnology park in Malaysia, has been set up in order to strengthen the country's infrastru...
Singapore: Healthcare across the Asia-Pacific is in a state of accelerated evolution due to not only changing demographi...
Singapore: Malaysian government's East Coast Economic Region Development Council (ECERDC), Malaysian Biotechnology Corp ...
Singapore: Malaysian biotech corp, the lead development agency for the biotech industry in Malaysia,has ventured into op...
Singapore: Malaysian Bio-XCell, a joint venture between Malaysian Biotechnology Corporation and UEM Sunrise, Malaysia, l...
Malaysia has geared itself to become a high-income developed nation by 2020. Working towards that goal, the government h...
Malaysia-based AseaCyte is emerging as an instrumental firm in the domain of human disease analysis, through its cell cu...
Most pharmaceutical companies are sitting on the patent cliff and their drug pipelines are facing severe exhaustion. The...
Singapore: Cancer is the biggest cause of mortality worldwide as the killer disease claimed an estimated 8.2 million liv...
Singapore: BP healthcare, a day care medical center operator, declared the opening of four new medical centers this year...
Indian apex court has made its intentions clear with the rejection of Novartis' plea to obtain patent protection for can...
A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing ...
